Challenges in Pharmacovigilance

This session of the Biosimilars 2019 will be looking into the future and FDA initiatives that have already been announced to include enhanced tracking and follow-up of post market issues, planned improvements in AERS, and pilots of new post market drug-monitoring strategies. Current challenges in pharmacovigilance, Adverse drug reactions with pharmaceutical products, Biosimilar guidelines for pharmacovigilance practice and pharmacoepidemiology are the points that shall be laid emphasis in this session.

 

  • Current problems in biosimilar pharmacovigilance
  • Adverse drug reactions with biologics and biosimilar products
  • Detection and evaluation of drug safety signals
  • Role of pharma industries in the improvement of pharmacovigilance system
  • Good pharmacovigilance practice and pharmacoepidemiology

Related Conference of Challenges in Pharmacovigilance

Challenges in Pharmacovigilance Conference Speakers